Human monoclonal antibodies to CTLA-4
In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
1. An antibody or an antigen-binding portion thereof that binds to CTLA-4, wherein said antibody comprises the heavy chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 7 and the light chain CDR1, CDR2, and CDR3 amino acid residues in SEQ ID NO: 20.
2. The antibody or antigen-binding portion according to claim 1 , wherein said antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 7 and a light chain comprising the amino acid sequence of SEQ ID NO: 20.
3. An antibody or an antigen-binding portion thereof that binds to CTLA-4, wherein said antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 7.
4. An antibody or an antigen-binding portion thereof that binds to CTLA-4, wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 20.
5. The antibody or antigen-binding portion according to claim 1 , wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab′) 2 fragment, an F v fragment, a single chain antibody, or a bispecific antibody.
6. The antibody or antigen-binding portion according to claim 2 , wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab′) 2 fragment, an F v fragment, a single chain antibody, or a bispecific antibody.
7. The antibody or antigen-binding portion according to claim 3 , wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab′) 2 fragment, an F v fragment, a single chain antibody, or a bispecific antibody.
8. The antibody or antigen-binding portion according to claim 4 , wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab′) 2 fragment, an F v fragment, a single chain antibody, or a bispecific antibody.
9. The antibody or antigen-binding portion according to claim 1 , wherein said antibody is an immunoglobulin G (IgG) molecule.
10. The antibody or antigen-binding portion according to claim 2 , wherein said antibody is an immunoglobulin G (IgG) molecule.
11. The antibody or antigen-binding portion according to claim 3 , wherein said antibody is an immunoglobulin G (IgG) molecule.
12. The antibody or antigen-binding portion according to claim 4 , wherein said antibody is an immunoglobulin G (IgG) molecule.
13. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 1 and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 2 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 3 and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 4 and a pharmaceutically acceptable carrier.
17. A method for treating cancer in a subject, comprising the step of administering to the subject the antibody or antigen-binding portion according to claim 1 .
18. A method for treating cancer in a subject, comprising the step of administering to the subject the antibody or antigen-binding portion according to claim 2 .
19. A method for treating cancer in a subject, comprising the step of administering to the subject the antibody or antigen-binding portion according to claim 3 .
20. A method for treating cancer in a subject, comprising the step of administering to the subject the antibody or antigen-binding portion according to claim 4 .
21. The method according to claim 17 , wherein the subject is human.
22. The method according to claim 18 , wherein the subject is human.
23. The method according to claim 19 , wherein the subject is human.
24. The method according to claim 20 , wherein the subject is human.